Evidence map›Paper›PMID 38830896›Full record

ArticleCell death & disease2024

Apolipoprotein O modulates cholesterol metabolism via NRF2/CYB5R3 independent of LDL receptor.

Jin Chen, Jiarui Hu, Xin Guo, Yang Yang, Donglu Qin, Xiaoyu Tang, Zhijie Huang, Fengjiao Wang, Die Hu, Daoquan Peng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Mitochondrial geneTranslational cancer research · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jin Chen *Department of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Jiarui Hu *Department of Spine Surgery, The Second Xiangya Hospital, Central South University, NO.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Xin GuoDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Yang YangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Donglu QinDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Xiaoyu TangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Zhijie HuangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Fengjiao WangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Die HuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Daoquan PengDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Bilian YuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Research Institute of Blood Lipid and Atherosclerosis, Central South University, No.139 Middle Renmin Road, Changsha, 410011, Hunan, China. yubilian@csu.edu.cn.ORCID 0000-0002-5701-5487

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81670420National Natural Science Foundation of China (National Science Foundation of China) 82170483
6 · The paper itself

Abstract

Apolipoprotein O (APOO) plays a critical intracellular role in regulating lipid metabolism. Here, we investigated the roles of APOO in metabolism and atherogenesis in mice. Hepatic APOO expression was increased in response to hyperlipidemia but was inhibited after simvastatin treatment. Using a novel APOO global knockout (Apoo

Indexed as

ApolipoproteinsCholesterolNF-E2-Related Factor 2Receptors, LDLAnimalsApolipoproteins EAtherosclerosisCytochrome-B(5) ReductaseHumansHyperlipidemiasLipid MetabolismLiverMiceMice, Inbred C57BLMice, KnockoutApolipoproteinsApolipoproteins EApoo protein, mouseCholesterolCyb5r3 protein, mouseCytochrome-B(5) ReductaseNfe2l2 protein, mouseNF-E2-Related Factor 2Receptors, LDL

Identifiers

PMID38830896
PMCPMC11148037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.